Ask AI
ProCE Banner Series

InterACT Oncology Team Training: Integrating Bispecific Antibodies Into Patient-Centered Management of DLBCL—Enhancing the Patient–Provider Therapeutic Connection

The content of this live event will help healthcare professionals in clinical decision-making for DLBCL. The activity will provide data on treatment plans for newly diagnosed and relapsed patients that reflect the latest evidence to help align with each patient’s needs and values.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This activity is intended for community hematology teams caring for patients with DLBCL, including medical oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals. 

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This certified educational activity aims to enhance clinical decision-making for DLBCL, ensuring that treatment plans for newly diagnosed and relapsed patients reflect the latest evidence and genuinely align with each patient’s needs and values. By improving multidisciplinary providers' knowledge, competence, and coordination, the program seeks to improve patient outcomes (higher remission rates, improved quality of life) and patient satisfaction with their care.

Target Audience
This activity is intended for community hematology teams caring for patients with DLBCL, including medical oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Differentiate high-risk features and unmet needs in newly diagnosed DLBCL to guide frontline treatment selection

  • Evaluate clinical trial data and guideline recommendations to effectively integrate bispecific antibodies into managing relapsed or refractory DLBCL

  • Formulate multidisciplinary strategies to identify, prevent, and manage cytokine release syndrome and related toxicities associated with bispecific antibodies

  • Incorporate patient goals and preferences into shared decision-making to optimize DLBCL treatment planning across the continuum of care

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC dba Decera Clinical Education and Smart Patients, Inc. Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: Specific to each event 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Smart Patients, Inc.

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by an educational grant from Genentech, a member of the Roche Group.

Genentech, a member of the Roche Group

Partners

Smart Patients, Inc.

ProCE Banner

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191